Eli Lilly and Company $LLY Shares Sold by New Covenant Trust Company N.A.

New Covenant Trust Company N.A. decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 13.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,538 shares of the company’s stock after selling 405 shares during the quarter. Eli Lilly and Company accounts for about 1.8% of New Covenant Trust Company N.A.’s investment portfolio, making the stock its 14th largest position. New Covenant Trust Company N.A.’s holdings in Eli Lilly and Company were worth $1,968,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. WestEnd Advisors LLC increased its stake in Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after purchasing an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC purchased a new stake in Eli Lilly and Company during the first quarter valued at about $27,000. Citizens National Bank Trust Department boosted its holdings in shares of Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after buying an additional 27 shares during the period. Financial Gravity Asset Management Inc. purchased a new position in shares of Eli Lilly and Company in the first quarter worth approximately $40,000. Finally, TD Capital Management LLC raised its holdings in shares of Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after acquiring an additional 31 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $724.73 on Monday. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The firm has a fifty day simple moving average of $734.15 and a 200-day simple moving average of $766.60. The stock has a market capitalization of $685.93 billion, a price-to-earnings ratio of 47.37, a PEG ratio of 1.01 and a beta of 0.47. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $937.00.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm’s revenue was up 37.6% compared to the same quarter last year. During the same period last year, the business posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, sell-side analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Insider Buying and Selling

In other Eli Lilly and Company news, Director J Erik Fyrwald purchased 1,565 shares of the business’s stock in a transaction dated Tuesday, August 12th. The stock was bought at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the acquisition, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gabrielle Sulzberger acquired 117 shares of the stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the purchase, the director owned 2,703 shares of the company’s stock, valued at $1,733,109.54. The trade was a 4.52% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 4,514 shares of company stock worth $2,894,841. 0.14% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms recently commented on LLY. JPMorgan Chase & Co. decreased their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a research note on Tuesday, September 16th. Cantor Fitzgerald reduced their target price on Eli Lilly and Company from $975.00 to $825.00 and set an “overweight” rating for the company in a report on Wednesday, August 13th. HSBC upgraded Eli Lilly and Company from a “reduce” rating to a “hold” rating and lifted their price target for the company from $675.00 to $700.00 in a report on Wednesday, August 27th. Leerink Partnrs downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 7th. Finally, Deutsche Bank Aktiengesellschaft lowered their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research note on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $939.61.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.